Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 2
1989 1
1990 1
1993 2
1997 1
1998 2
1999 2
2000 1
2002 3
2003 2
2004 3
2005 3
2006 2
2007 5
2008 1
2009 2
2010 2
2011 1
2012 6
2013 6
2014 5
2015 3
2016 7
2017 12
2018 8
2019 14
2020 28
2021 33
2022 28
2023 39
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for hassan attain
Your search for Hassan Attan retrieved no results
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
At week 116, the difference in the amyloid level on PET between the gantenerumab group and the placebo group was -66.44 and -56.46 centiloids in the GRADUATE I and II trials, respectively, and amyloid-negative status was attained in 28.0% and 26.8% of the participants rece …
At week 116, the difference in the amyloid level on PET between the gantenerumab group and the placebo group was -66.44 and -56.46 centiloid …
Intermittent Fasting: Benefits, Side Effects, Quality of Life, and Knowledge of the Saudi Population.
Shalabi H, Hassan AS 4th, Al-Zahrani FA, Alarbeidi AH, Mesawa M, Rizk H, Aljubayri AA. Shalabi H, et al. Cureus. 2023 Feb 7;15(2):e34722. doi: 10.7759/cureus.34722. eCollection 2023 Feb. Cureus. 2023. PMID: 36909028 Free PMC article.
IF has shown many benefits for people who are obese and are trying to lose weight and attain a healthy lifestyle. The aim of our study was to evaluate the efficacy of IF and how it can be used as a daily lifestyle as well as to measure the knowledge of the IF diet among th …
IF has shown many benefits for people who are obese and are trying to lose weight and attain a healthy lifestyle. The aim of our stud …
Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021.
GBD 2021 Sickle Cell Disease Collaborators. GBD 2021 Sickle Cell Disease Collaborators. Lancet Haematol. 2023 Aug;10(8):e585-e599. doi: 10.1016/S2352-3026(23)00118-7. Epub 2023 Jun 15. Lancet Haematol. 2023. PMID: 37331373 Free PMC article.
Without comprehensive strategies to address morbidity and mortality associated with sickle cell disease, attainment of SDG 3.1, 3.2, and 3.4 is uncertain. Widespread data gaps and correspondingly high uncertainty in the estimates highlight the urgent need for routine and s …
Without comprehensive strategies to address morbidity and mortality associated with sickle cell disease, attainment of SDG 3.1, 3.2, …
Global, regional, and national mortality among young people aged 10-24 years, 1950-2019: a systematic analysis for the Global Burden of Disease Study 2019.
GBD 2019 Adolescent Mortality Collaborators. GBD 2019 Adolescent Mortality Collaborators. Lancet. 2021 Oct 30;398(10311):1593-1618. doi: 10.1016/S0140-6736(21)01546-4. Epub 2021 Oct 28. Lancet. 2021. PMID: 34755628 Free PMC article.
We then analyse the association between mortality in people aged 10-24 years and socioeconomic development using the GBD Socio-demographic Index (SDI), a composite measure based on average national educational attainment in people older than 15 years, total fertility rate …
We then analyse the association between mortality in people aged 10-24 years and socioeconomic development using the GBD Socio-demographic I …
Telemedicine and the patient with sepsis.
Badawi O, Hassan E. Badawi O, et al. Crit Care Clin. 2015 Apr;31(2):291-304. doi: 10.1016/j.ccc.2014.12.007. Epub 2015 Jan 17. Crit Care Clin. 2015. PMID: 25814455 Review.
Technology associated with telemedicine may help in screening, identifying, and monitoring the attainment of the severe sepsis bundle elements in a timely manner. ...
Technology associated with telemedicine may help in screening, identifying, and monitoring the attainment of the severe sepsis bundle …
The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories.
Lazarus JV, Han H, Mark HE, Alqahtani SA, Schattenberg JM, Soriano JB, White TM, Zelber-Sagi S, Dirac MA; GBD Fatty Liver Disease Sustainable Development Goal Collaborators. Lazarus JV, et al. Hepatology. 2023 Sep 1;78(3):911-928. doi: 10.1097/HEP.0000000000000361. Epub 2023 Apr 18. Hepatology. 2023. PMID: 37595128 Free PMC article.
The first included 6 indicators (child wasting, child overweight, noncommunicable disease mortality, a universal health coverage service coverage index, health worker density, and education attainment), covering 195 countries and territories between 1990 and 2017. ...
The first included 6 indicators (child wasting, child overweight, noncommunicable disease mortality, a universal health coverage service cov …
5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy.
Valencia-Lazcano AA, Hassan D, Pourmadadi M, Shamsabadipour A, Behzadmehr R, Rahdar A, Medina DI, Díez-Pascual AM. Valencia-Lazcano AA, et al. Eur J Med Chem. 2023 Jan 15;246:114995. doi: 10.1016/j.ejmech.2022.114995. Epub 2022 Dec 1. Eur J Med Chem. 2023. PMID: 36493619 Review.
Furthermore, co-delivery systems of 5-FU with other drugs (e.g. paclitaxel, gelatin-doxorubicin and naproxen) have been reviewed, which aid to attain better bioavailability, higher effectiveness at a lower concentration and lower toxicity. ...
Furthermore, co-delivery systems of 5-FU with other drugs (e.g. paclitaxel, gelatin-doxorubicin and naproxen) have been reviewed, which aid …
Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Fertility and Forecasting Collaborators. GBD 2021 Fertility and Forecasting Collaborators. Lancet. 2024 Mar 19:S0140-6736(24)00550-6. doi: 10.1016/S0140-6736(24)00550-6. Online ahead of print. Lancet. 2024. PMID: 38521087 Free article.
CCF50 was modelled using an ensemble approach in which three sub-models (with two, three, and four covariates variously consisting of female educational attainment, contraceptive met need, population density in habitable areas, and under-5 mortality) were given equal weigh …
CCF50 was modelled using an ensemble approach in which three sub-models (with two, three, and four covariates variously consisting of female …
Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.
Hassan J, Haigh C, Ahmed T, Uddin MJ, Das DB. Hassan J, et al. Pharmaceutics. 2022 May 16;14(5):1066. doi: 10.3390/pharmaceutics14051066. Pharmaceutics. 2022. PMID: 35631652 Free PMC article. Review.
The use of dissolvable microneedles for COVID-19 vaccination could act as a major paradigm shift in attaining the desired goal to vaccinate billions in the shortest time possible. ...
The use of dissolvable microneedles for COVID-19 vaccination could act as a major paradigm shift in attaining the desired goal to vac …
Real-world challenges for hepatitis C virus medications: a critical overview.
Shahid I, AlMalki WH, Hassan S, Hafeez MH. Shahid I, et al. Crit Rev Microbiol. 2018 Mar;44(2):143-160. doi: 10.1080/1040841X.2017.1329277. Epub 2017 May 25. Crit Rev Microbiol. 2018. PMID: 28539069 Review.
From 2010, the landscape of hepatitis C therapeutics has been changed rapidly, and today we are standing at a cusp of a pharmacological revolution where highly effective and interferon (IFN)-free direct acting antivirals (DAAs) are already on the market. Such treatment paradigms …
From 2010, the landscape of hepatitis C therapeutics has been changed rapidly, and today we are standing at a cusp of a pharmacological revo …
228 results